Add-on fluvoxamine treatment for schizophrenia: an updated meta-analysis of randomized controlled trials.
In: European Archives of Psychiatry & Clinical Neuroscience, Jg. 263 (2013-12-01), Heft 8, S. 633-641
Online
academicJournal
Zugriff:
We performed an updated meta-analysis of fluvoxamine add-on therapy in patients with schizophrenia treated with antipsychotics based on two previous meta-analyses (Sepehry et al., in J Clin Psychiatry 68:604–610, 2007 and Singh et al., in Br J Psychiatry J Mental Sci 197:174–179, 2010 ). We searched PubMed, the Cochrane Library database, and PsycINFO up to January 2013. We conducted a systematic review and meta-analysis of individual patient data from randomized controlled trials comparing fluvoxamine add-on therapy with placebo. The risk ratio (RR), 95 % confidence intervals (CI), and standardized mean difference (SMD) were calculated. Seven studies (total n = 272) were identified. These included two clozapine studies, one olanzapine study, one second-generation antipsychotic (SGA) monotherapy study, and three first-generation antipsychotics (FGAs) monotherapy studies. There were significant effect of fluvoxamine add-on therapy on overall (SMD = −0.46, CI = −0.75 to −0.16, p = 0.003, I2 = 0 %, 5 studies, n = 180) and negative symptoms (SMD = −0.44, CI = −0.74 to −0.14, p = 0.004, I2 = 0 %, 5 studies, n = 180). However, fluvoxamine add-on therapy showed no significant effects on positive symptoms, depressive symptoms, and discontinuations from any cause or adverse events. Fluvoxamine add-on therapy in patients primarily treated with SGAs improved overall ( p = 0.02) but not negative symptoms ( p = 0.31). On the other hand, fluvoxamine add-on therapy in patients primarily treated with FGAs improved both overall ( p = 0.04) and negative symptoms ( p = 0.004) compared with control groups. Our results suggest that fluvoxamine add-on therapy is more beneficial on the psychopathology (especially negative symptoms) than controls in patients with schizophrenia who are primarily treated with FGAs. Given that a small number of studies were included in this meta-analysis, the results should be treated with caution. [ABSTRACT FROM AUTHOR]
Titel: |
Add-on fluvoxamine treatment for schizophrenia: an updated meta-analysis of randomized controlled trials.
|
---|---|
Autor/in / Beteiligte Person: | Kishi, Taro ; Hirota, Tomoya ; Iwata, Nakao |
Link: | |
Zeitschrift: | European Archives of Psychiatry & Clinical Neuroscience, Jg. 263 (2013-12-01), Heft 8, S. 633-641 |
Veröffentlichung: | 2013 |
Medientyp: | academicJournal |
ISSN: | 0940-1334 (print) |
DOI: | 10.1007/s00406-013-0406-3 |
Schlagwort: |
|
Sonstiges: |
|